

CITATION REPORT

List of articles citing

Comprehensive Analysis of Hypermutation in Human Cancer

DOI: 10.1016/j.cell.2017.09.048
Cell, 2017, 171, 1042-1056.e10.

Source: <https://exaly.com/paper-pdf/66917357/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
540	Cancer Evolution: No Room for Negative Selection. <i>Cell</i> , 2017 , 171, 987-989	56.2	12
539	Cancer genomics: The driving force of cancer evolution. 2017 , 18, 703		7
538	The landscape of genomic alterations across childhood cancers. 2018 , 555, 321-327		603
537	Temozolomide-associated hypermutation in gliomas. 2018 , 20, 1300-1309		69
536	The rise of a novel classification system for endometrial carcinoma; integration of molecular subclasses. 2018 , 244, 538-549		86
535	Functional Analysis of Cancer-Associated DNA Polymerase β Variants in. 2018 , 8, 1019-1029		27
534	Everybody In! No Bouncers at Tumor Gates. 2018 , 34, 85-87		2
533	Distinct mutational signatures characterize concurrent loss of polymerase proofreading and mismatch repair. 2018 , 9, 1746		95
532	Highlights from the Literature. 2018 , 20, 441-444		78
531	Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade. 2018 , 2018,		22
530	Genomic Heterogeneity Underlies Mixed Response to Tropomyosin Receptor Kinase Inhibition in Recurrent Glioma. 2018 , 2,		1
529	Mutational Signature and Transcriptomic Classification Analyses as the Decisive Diagnostic Tools for a Cancer of Unknown Primary. 2018 , 2,		2
528	Tumor mutational burden in non-small cell lung cancer-the pathologist's point of view. 2018 , 7, 716-721		8
527	Approach to evaluating tumor mutational burden in routine clinical practice. 2018 , 7, 678-681		13
526	Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma. 2018 , 18, 1221		4
525	Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade. 2018 , 7, 32		20
524	Sustainable Response of a Patient With Metastasized Pancreatic Cancer and a Hypermutational Phenotype to Immunotherapy. New Therapeutic Concept for a Rare Subtype?. 2018 , 2, 1-6		1

523	Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. 2018 , 18, 1082	29
522	Criticality in tumor evolution and clinical outcome. 2018 , 115, E11101-E11110	13
521	Rare Stochastic Expression of O6-Methylguanine- DNA Methyltransferase (MGMT) in MGMT-Negative Melanoma Cells Determines Immediate Emergence of Drug-Resistant Populations upon Treatment with Temozolomide In Vitro and In Vivo. 2018 , 10,	6
520	Integrating somatic variant data and biomarkers for germline variant classification in cancer predisposition genes. 2018 , 39, 1542-1552	23
519	The DNA damage response in immunotherapy and radiation. 2018 , 3, 527-533	18
518	Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden. 2018 , 7, e1526613	40
517	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. 2018 , 9, 1878	69
516	Sustained complete response of recurrent glioblastoma to combined checkpoint inhibition in a young patient with constitutional mismatch repair deficiency. 2018 , 65, e27389	17
515	Integrating the DNA damage and protein stress responses during cancer development and treatment. 2018 , 246, 12-40	54
514	Following Ribosome Footprints to Understand Translation at a Genome Wide Level. 2018 , 16, 167-176	17
513	CSF1R-Expressing Tumor-Associated Macrophages, Smoking and Survival in Lung Adenocarcinoma: Analyses Using Quantitative Phosphor-Integrated Dot Staining. 2018 , 10,	9
512	The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. 2018 , 10, 1758835918786223	38
511	Osteosarcoma: Accelerating Progress Makes for a Hopeful Future. 2018 , 8, 4	113
510	Advances in Molecular Profiling and Categorisation of Pancreatic Adenocarcinoma and the Implications for Therapy. 2018 , 10,	14
509	Eukaryotic DNA polymerases. 2018 , 53, 77-87	49
508	PolII Instability Drives Replication Stress, Abnormal Development, and Tumorigenesis. 2018 , 70, 707-721.e7	40
507	Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. 2018 , 8, 7119	25
506	Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation. 2018 , 29, 1800-1806	22

505	Targeting the cancer mutanome of breast cancer. 2018 , 24, 703-704	9
504	Delineating a new feature of constitutional mismatch repair deficiency (CMMRD) syndrome: breast cancer. 2019 , 18, 105-108	5
503	Implementing precision cancer medicine in the genomic era. 2019 , 55, 16-27	16
502	Machine learning and feature selection for drug response prediction in precision oncology applications. 2019 , 11, 31-39	76
501	Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues. 2019 , 116, 16987-16996	6
500	Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors. 2019 , 36, 2638-2678	86
499	Spatial Distance Correlates With Genetic Distance in Diffuse Glioma. 2019 , 9, 676	4
498	Machine learning and data mining frameworks for predicting drug response in cancer: An overview and a novel in silico screening process based on association rule mining. 2019 , 203, 107395	35
497	Clinical implications of mismatch repair deficiency in prostate cancer. 2019 , 15, 2395-2411	11
496	Tumor Mutation Burden and Prognosis in Patients with Colorectal Cancer Treated with Adjuvant Fluoropyrimidine and Oxaliplatin. 2019 , 25, 6141-6147	51
495	Contribution of New Adenomatous Polyposis Predisposition Genes in an Unexplained Attenuated Spanish Cohort by Multigene Panel Testing. 2019 , 9, 9814	5
494	Modeling clinical and molecular covariates of mutational process activity in cancer. 2019 , 35, i492-i500	9
493	Management of recurrent or refractory Ewing sarcoma: A systematic review of phase II clinical trials in the last 15 years. 2019 , 18, 348-358	5
492	Optimization of Population Frequency Cutoffs for Filtering Common Germline Polymorphisms from Tumor-Only Next-Generation Sequencing Data. 2019 , 21, 903-912	5
491	Genomic sequencing identifies WNK2 as a driver in hepatocellular carcinoma and a risk factor for early recurrence. 2019 , 71, 1152-1163	28
490	Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small-Cell Lung Cancer. 2019 , 23, 507-520	22
489	Preanalytic Variables and Tissue Stewardship for Reliable Next-Generation Sequencing (NGS) Clinical Analysis. 2019 , 21, 756-767	15
488	Mutational burden and signatures in 4000 Japanese cancers provide insights into tumorigenesis and response to therapy. 2019 , 110, 2620-2628	15

487	Comprehensive analysis of potential immunotherapy genomic biomarkers in 1000 Chinese patients with cancer. 2019 , 8, 4699-4708	30
486	An updated review of microsatellite instability in the era of next-generation sequencing and precision medicine. 2019 , 46, 261-270	29
485	5-Fluorouracil treatment induces characteristic T>G mutations in human cancer. 2019 , 10, 4571	84
484	Comprehensive analysis of POLE and POLD1 Gene Variations identifies cancer patients potentially benefit from immunotherapy in Chinese population. 2019 , 9, 15767	21
483	Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome. 2019 , 5,	12
482	A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability and Pan-Tumor Characterization of 1000 Microsatellite Instability-High Cases in 67,000 Patient Samples. 2019 , 21, 1053-1066	72
481	Ultra-Mutation in Wild-Type Glioblastomas of Patients Younger than 55 Years is Associated with Defective Mismatch Repair, Microsatellite Instability, and Giant Cell Enrichment. 2019 , 11,	12
480	Comprehensive genomic profiling of glioblastoma tumors, BTICs, and xenografts reveals stability and adaptation to growth environments. 2019 , 116, 19098-19108	23
479	Immunotherapeutic Challenges for Pediatric Cancers. 2019 , 15, 38-48	18
478	When Should Tumor Genomic Profiling Prompt Consideration of Germline Testing?. 2019 , 15, 465-473	27
477	Current Perspectives in Cancer Immunotherapy. 2019 , 11,	101
476	Cryo-EM structure and dynamics of eukaryotic DNA polymerase β holoenzyme. 2019 , 26, 955-962	28
475	Unraveling the Heterogeneous Mutational Signature of Spontaneously Developing Tumors in MLH1 Mice. 2019 , 11,	6
474	Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions. 2019 , 58, 578-588	96
473	A recurrent cancer-associated substitution in DNA polymerase β produces a hyperactive enzyme. 2019 , 10, 374	30
472	Implementing TMB measurement in clinical practice: considerations on assay requirements. 2019 , 4, e000442	136
471	A New Molecular Taxonomy to Predict Immune Checkpoint Inhibitor Sensitivity in Prostate Cancer. 2019 , 24, 430-432	14
470	Somatic mutational signatures in polyposis and colorectal cancer. 2019 , 69, 62-72	10

469	Genomics-Enabled Precision Medicine for Cancer. 2019 , 178, 137-169	6
468	Homologous recombination and DNA repair mutations in patients treated with carboplatin and nab-paclitaxel for metastatic non-small cell lung cancer. 2019 , 134, 167-173	4
467	Integrative genomic analysis of matched primary and metastatic pediatric osteosarcoma. 2019 , 249, 319-331	19
466	Associating somatic mutations to clinical outcomes: a pan-cancer study of survival time. 2019 , 11, 37	4
465	Association Between Preanalytical Factors and Tumor Mutational Burden Estimated by Next-Generation Sequencing-Based Multiplex Gene Panel Assay. 2019 , 24, e1401-e1408	3
464	Blocking the PD-1/PD-L1 axis in advanced prostate cancer: are we moving in the right direction?. 2019 , 7, S7	17
463	Progressing from Recurring Tissue Injury to Genomic Instability: A New Mechanism of Neutrophil Pathogenesis. 2019 , 38, 747-753	8
462	Extensive loss of cell-cycle and DNA repair genes in an ancient lineage of bipolar budding yeasts. 2019 , 17, e3000255	59
461	Integrating Biomarkers and Targeted Therapy Into Colorectal Cancer Management. 2019 , 39, 207-215	11
460	Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. 2019 , 37, 1547-1557	138
459	Measuring Clonal Evolution in Cancer with Genomics. 2019 , 20, 309-329	26
458	Portrait of a cancer: mutational signature analyses for cancer diagnostics. 2019 , 19, 457	51
457	Anti-CD166/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. 2019 , 38, 168	26
456	Finding driver mutations in cancer: Elucidating the role of background mutational processes. 2019 , 15, e1006981	32
455	Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study. 2019 , 110, 1480-1490	117
454	A novel 4-gene prognostic signature for hypermutated colorectal cancer. 2019 , 11, 1985-1996	9
453	Undifferentiated Sarcomas Develop through Distinct Evolutionary Pathways. 2019 , 35, 441-456.e8	35
452	Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. 2019 , 25, 4592-4602	241

451	Low frequency of POLD1 and POLE exonuclease domain variants in patients with multiple colorectal polyps. 2019 , 7, e00603	7
450	Comprehensive assay for the molecular profiling of cancer by target enrichment from formalin-fixed paraffin-embedded specimens. 2019 , 110, 1464-1479	28
449	Whole-exome sequencing revealed mutational profiles of giant cell glioblastomas. 2019 , 29, 782-792	8
448	The genomic landscape of pediatric cancers: Implications for diagnosis and treatment. 2019 , 363, 1170-1175	53
447	Integrated Analysis of Germline and Tumor DNA Identifies New Candidate Genes Involved in Familial Colorectal Cancer. 2019 , 11,	8
446	Functional Repair Assay for the Diagnosis of Constitutional Mismatch Repair Deficiency From Non-Neoplastic Tissue. 2019 , 37, 461-470	17
445	Prospective Clinical Sequencing of Adult Glioma. 2019 , 18, 991-1000	7
444	Translating insights into tumor evolution to clinical practice: promises and challenges. 2019 , 11, 20	34
443	Approaches to functionally validate candidate genetic variants involved in colorectal cancer predisposition. 2019 , 69, 27-40	3
442	Diagnosis and management of a recurrent polymerase-epsilon (POLE)-mutated endometrial cancer. 2019 , 153, 471-478	10
441	Genetic Factors Associated with a Poor Outcome in Head and Neck Cancer Patients Receiving Definitive Chemoradiotherapy. 2019 , 11,	12
440	Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer. 2019 , 37, 286-295	203
439	BRCA gene mutations do not shape the extent and organization of tumor infiltrating lymphocytes in triple negative breast cancer. 2019 , 450, 88-97	21
438	Current and Future Strategies for Treatment of Relapsed Neuroblastoma. 2019 , 263-281	0
437	Challenges to curing primary brain tumours. 2019 , 16, 509-520	284
436	POLE proofreading defects: Contributions to mutagenesis and cancer. 2019 , 76, 50-59	22
435	-mutated clear cell cervical cancer associated with in-utero diethylstilbestrol exposure. 2019 , 28, 15-17	4
434	Mutational and Antigenic Landscape in Tumor Progression and Cancer Immunotherapy. 2019 , 29, 396-416	37

433	Emerging Role of the Pathologist in Precision Medicine for HCC. 2019 , 64, 928-933	3
432	[Going beyond microsatellite instability for immunotherapy in metastatic colorectal cancer: Consensus molecular subtypes and tumor mutational burden]. 2019 , 106, 151-161	2
431	Germline mutation in a child with hypermutated medulloblastoma and features of constitutional mismatch repair deficiency. 2019 , 5,	12
430	B-cell acute lymphoblastic leukemia with high mutation burden presenting in a child with constitutional mismatch repair deficiency. 2019 , 3, 1795-1798	6
429	Reversion of tumor hepatocytes to normal hepatocytes during liver tumor regression in an oncogene-expressing transgenic zebrafish model. 2019 , 12,	8
428	Predicting Tumor Mutational Burden from Liver Cancer Pathological Images Using Convolutional Neural Network. 2019 ,	6
427	[Constitutional MMR deficiency: Genetic bases and clinical implications]. 2019 , 106, 162-172	2
426	The prognostic value of tumor mutation burden in -mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base. 2019 , 11, 4507-4515	14
425	Germline and proofreading domain mutations in endometrial carcinoma from Middle Eastern region. 2019 , 19, 334	7
424	Recurrent PTPRT/JAK2 mutations in lung adenocarcinoma among African Americans. 2019 , 10, 5735	15
423	Mutational signatures in colon cancer. 2019 , 12, 788	2
422	Management of Juvenile Polyposis Syndrome in Children and Adolescents: A Position Paper From the ESPGHAN Polyposis Working Group. 2019 , 68, 453-462	36
421	Immunotherapies for pediatric cancer: current landscape and future perspectives. 2019 , 38, 573-594	13
420	Lynch Syndrome With Germline Mutation in a Patient With Primary Anaplastic Glioneuronal Tumor.. 2019 , 3, 1-6	
419	A squamous cell carcinoma in a young woman with Lynch syndrome. 2019 , 18, 193-196	5
418	Biomarkers for Programmed Death-1 Inhibition in Prostate Cancer. 2019 , 24, 444-448	13
417	Risk stratification by somatic mutation burden in Ewing sarcoma. 2019 , 125, 1357-1364	13
416	Deciphering molecular properties of hypermutated gastrointestinal cancer. 2019 , 23, 370-379	6

415	Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels. 2019 , 144, 2303-2312	50
414	Comutation and exclusion analysis in human tumors: A tool for cancer biology studies and for rational selection of multitargeted therapeutic approaches. 2019 , 40, 413-425	
413	Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer. 2019 , 38, 1661-1675	10
412	Novel POLE pathogenic germline variant in a family with multiple primary tumors results in distinct mutational signatures. 2019 , 40, 36-41	12
411	Clinical Impact of Tumor Mutational Burden in Neuroblastoma. 2019 , 111, 695-699	16
410	Molecular characterization of endometrial cancer and therapeutic implications. 2019 , 31, 24-30	16
409	Hypermutagenesis in untreated adult gliomas due to inherited mismatch mutations. 2019 , 144, 3023-3030	12
408	Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. 2019 , 16, 227-240	75
407	mTOR Inhibitors as a New Therapeutic Strategy in Treatment Resistant Epilepsy in Hemimegalencephaly: A Case Report. 2019 , 34, 132-138	16
406	Circulating cell-free tumor DNA analysis in pediatric cancers. 2020 , 72, 100819	16
405	Pediatric high-grade glioma resources from the Children's Brain Tumor Tissue Consortium. 2020 , 22, 163-165	9
404	Tumor Mutational Burden as a Predictive Biomarker for Response to Immune Checkpoint Inhibitors: A Review of Current Evidence. 2020 , 25, e147-e159	86
403	The missing heritability of familial colorectal cancer. 2020 , 35, 221-231	14
402	Biomarker-guided therapy for colorectal cancer: strength in complexity. 2020 , 17, 11-32	103
401	Genomic instabilities: kind, effects, and roles in the immortality of tumor cell populations. 2020 , 571-580	
400	Recent advances in genetic predisposition to pediatric acute lymphoblastic leukemia. 2020 , 13, 55-70	18
399	High-risk Stage III colon cancer patients identified by a novel five-gene mutational signature are characterized by upregulation of IL-23A and gut bacterial translocation of the tumor microenvironment. 2020 , 146, 2027-2035	24
398	Tumoral and immune heterogeneity in an anti-PD-1-responsive glioblastoma: a case study. 2020 , 6,	2

397	Simultaneous osteosarcoma and renal cell carcinoma with BRCA1 mutation in a young male adult with prior oligodendroglioma. 2020 , 67, e28116	2
396	High mutational burden in colorectal carcinomas with monoallelic POLE mutations: absence of allelic loss and gene promoter methylation. 2020 , 33, 1220-1231	3
395	PD-1 and PD-L1 Expression in Osteosarcoma: Which Specimen to Evaluate?. 2020 , 42, 482-487	5
394	Applied Genomics and Public Health Cancer Genomics. 2020 , 53-72	
393	Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1-2 trial. 2020 , 21, 121-133	93
392	Interpretation of somatic POLE mutations in endometrial carcinoma. 2020 , 250, 323-335	70
391	The genomics of undifferentiated sarcoma of soft tissue: Progress, challenges and opportunities. 2020 , 61, 42-55	7
390	Immune Checkpoint Inhibition in Colorectal Cancer: Microsatellite Instability and Beyond. 2020 , 15, 11-24	24
389	Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study. 2020 , 21, 134-144	47
388	Patterns of germline and somatic mutations in 16 genes associated with mismatch repair function or containing tandem repeat sequences. 2020 , 9, 476-486	5
387	Molecular characterization of endometrial cancer and therapeutic implications. 2020 , 32, 76-83	8
386	How Should Cancer Models Be Constructed?. 2020 , 27, 1073274820962008	4
385	Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With -Mutated Glioblastoma and -Deficient Lynch Syndrome. 2020 , 4,	2
384	Analysis of mutational and proteomic heterogeneity of gastric cancer suggests an effective pipeline to monitor post-treatment tumor burden using circulating tumor DNA. 2020 , 15, e0239966	1
383	An Introduction to the Current Management of Colorectal Cancer in the Era of Personalized Oncology. 2020 , 1-27	
382	Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective. 2020 , 133, 2466-2475	0
381	Whole genome, transcriptome and methylome profiling enhances actionable target discovery in high-risk pediatric cancer. 2020 , 26, 1742-1753	69
380	Next-generation sequencing analysis of endometrial screening liquid-based cytology specimens: a comparative study to tissue specimens. 2020 , 13, 101	12

379	Spontaneous Polyploids and Antimutators Compete During the Evolution of Mutator Cells. 2020 , 215, 959-974	7
378	Postzygotic Somatic Mutations in the Human Brain Expand the Threshold-Liability Model of Schizophrenia. 2020 , 11, 587162	3
377	Prediction of driver variants in the cancer genome via machine learning methodologies. 2021 , 22,	1
376	[Genetic instability, a factor limiting the efficiency of targeted therapies in solid oncology]. 2020 , 107, 1161-1170	
375	Translational Pancreatic Cancer Research. 2020 ,	1
374	From Banding to BAM Files: Genomics Informs Diagnosis and Precision Medicine for Brain Tumors. 2020 , 13, 343-347	
373	Emerging trends in gene-modified-based chimeric antigen receptor-engineered T-cellular therapy for malignant tumors: The lesson from leukemia to pediatric brain tumors. 2020 , 83, 719-724	2
372	Role of POLE and POLD1 in familial cancer. 2020 , 22, 2089-2100	23
371	Cell plasticity and genomic instability in cancer evolution. 2020 , 1, 301-309	1
370	Germline Profiling and Molecular Characterization of Early Onset Metastatic Colorectal Cancer. 2020 , 10, 568911	6
369	Tumour neoantigen heterogeneity thresholds provide a time window for combination immunotherapy. 2020 , 17, 20200736	4
368	Choosing tumor mutational burden wisely for immunotherapy: A hard road to explore. 2020 , 1874, 188420	9
367	Whole-Exome Profiling of NSCLC Among African Americans. 2020 , 15, 1880-1892	8
366	Germline RAD54L with somatic POLE defect implicated in Hypermutation phenotype: case report. 2020 , 20, 255	1
365	Mismatch repair and DNA polymerase β proofreading prevent catastrophic accumulation of leading strand errors in cells expressing a cancer-associated DNA polymerase β variant. 2020 , 48, 9124-9134	4
364	Patient-derived cells from recurrent tumors that model the evolution of -mutant glioma. 2020 , 2, vdaa088	7
363	Cancers from Novel -Mutant Mouse Models Provide Insights into Polymerase-Mediated Hypermutagenesis and Immune Checkpoint Blockade. 2020 , 80, 5606-5618	6
362	Germline-driven replication repair-deficient high-grade gliomas exhibit unique hypomethylation patterns. 2020 , 140, 765-776	8

361	Pembrolizumab Activity in Recurrent High-Grade Gliomas with Partial or Complete Loss of Mismatch Repair Protein Expression: A Monocentric, Observational and Prospective Pilot Study. 2020 , 12,	19
360	Structure of eukaryotic DNA polymerase β bound to the PCNA clamp while encircling DNA. 2020 , 117, 30344-30353	13
359	Clinical impact of a cancer genomic profiling test using an in-house comprehensive targeted sequencing system. 2020 , 111, 3926-3937	8
358	Characterizing temporal genomic heterogeneity in pediatric low-grade gliomas. 2020 , 8, 182	1
357	Novel Antibiotics Targeting Bacterial Replicative DNA Polymerases. 2020 , 9,	3
356	Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. 2020 , 10, 1808-1825	91
355	Therapeutic targeting of the DNA damage response in prostate cancer. 2020 , 32, 216-222	6
354	Immune Cytolytic Activity for Comprehensive Understanding of Immune Landscape in Hepatocellular Carcinoma. 2020 , 12,	30
353	Genetic, structural, and functional characterization of POLE polymerase proofreading variants allows cancer risk prediction. 2020 , 22, 1533-1541	9
352	Defined lifestyle and germline factors predispose Asian populations to gastric cancer. 2020 , 6, eaav9778	16
351	Tumor mutational burden and driver mutations: Characterizing the genomic landscape of pediatric brain tumors. 2020 , 67, e28338	10
350	High tumor mutation burden is associated with DNA damage repair gene mutation in breast carcinomas. 2020 , 15, 50	15
349	Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?. 2020 , 40, 1-18	8
348	Genome-wide cell-free DNA mutational integration enables ultra-sensitive cancer monitoring. 2020 , 26, 1114-1124	63
347	POLE Mutation Spectra Are Shaped by the Mutant Allele Identity, Its Abundance, and Mismatch Repair Status. 2020 , 78, 1166-1177.e6	10
346	DNA polymerase β relies on a unique domain for efficient replisome assembly and strand synthesis. 2020 , 11, 2437	6
345	Position paper: Challenges and specific strategies for constitutional mismatch repair deficiency syndrome in low-resource settings. 2020 , 67, e28309	8
344	Phase and context shape the function of composite oncogenic mutations. 2020 , 582, 100-103	13

343	Clinical and Molecular Correlates of Tumor Mutation Burden in Non-Small Cell Lung Cancer. 2020 , 146, 36-41	7
342	Exploiting Temozolomide-Induced Hypermutation With Pembrolizumab in a Refractory High-Grade Neuroendocrine Neoplasm: A Proof-of-Concept Case.. 2020 , 4, 614-619	5
341	Immune-checkpoint inhibitors and metastatic prostate cancer therapy: Learning by making mistakes. 2020 , 88, 102057	13
340	Sarcoma and the 100,000 Genomes Project: our experience and changes to practice. 2020 , 6, 297-307	6
339	Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADV1412): a multicentre, open-label, single-arm, phase 1-2 trial. 2020 , 21, 541-550	101
338	Nivolumab in paediatric cancer: children are not little adults. 2020 , 21, 474-476	1
337	ecTMB: a robust method to estimate and classify tumor mutational burden. 2020 , 10, 4983	9
336	Immune-Based Approaches for the Treatment of Pediatric Malignancies. 2020 , 4, 353-370	2
335	LOXL2 Expression Status Is Correlated With Molecular Characterizations of Cervical Carcinoma and Associated With Poor Cancer Survival via Epithelial-Mesenchymal Transition (EMT) Phenotype. 2020 , 10, 284	13
334	Tumor Microenvironment. 2020 ,	6
333	Landscape and function of multiple mutations within individual oncogenes. 2020 , 582, 95-99	41
332	Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes. 2020 , 6, 589-590	3
331	Evaluation of POLE/POLD1 Variants as Potential Biomarkers for Immune Checkpoint Inhibitor Treatment Outcomes-Reply. 2020 , 6, 590	1
330	Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study. 2020 , 15, 1177-1189	45
329	POLE and POLD1 germline exonuclease domain pathogenic variants, a rare event in colorectal cancer from the Middle East. 2020 , 8, e1368	4
328	Matching cell lines with cancer type and subtype of origin via mutational, epigenomic, and transcriptomic patterns. 2020 , 6,	18
327	Into the wild: new yeast genomes from natural environments and new tools for their analysis. 2020 , 20,	11
326	Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer. 2020 , 16, e1008572	14

325	The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research. 2020 , 26, 181-187	69
324	Two main mutational processes operate in the absence of DNA mismatch repair. 2020 , 89, 102827	10
323	Primary mammary angiosarcomas harbor frequent mutations in KDR and PIK3CA and show evidence of distinct pathogenesis. 2020 , 33, 1518-1526	6
322	Tumor antigens in glioma. 2020 , 47, 101385	19
321	A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo. 2020 , 52, 146-159	54
320	Prevalence and mutational determinants of high tumor mutation burden in breast cancer. 2020 , 31, 387-394	95
319	Quantitative Proteomics of the Cancer Cell Line Encyclopedia. <i>Cell</i> , 2020 , 180, 387-402.e16	56.2 210
318	ACCELERATE and European Medicines Agency Paediatric Strategy Forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients. 2020 , 127, 52-66	26
317	Pediatric hemispheric high-grade glioma: targeting the future. 2020 , 39, 245-260	16
316	Mutational landscape and patterns of clonal evolution in relapsed pediatric acute lymphoblastic leukemia. 2020 , 1, 96-111	44
315	Recurrent gene mutations detected in canine mast cell tumours by next generation sequencing. 2020 , 18, 509-518	1
314	An Exon Signature to Estimate the Tumor Mutational Burden of Right-sided Colon Cancer Patients. 2020 , 11, 883-892	2
313	An update on the CNS manifestations of brain tumor polyposis syndromes. 2020 , 139, 703-715	19
312	Microsatellite instability: a review of what the oncologist should know. 2020 , 20, 16	102
311	Tumor Mutational Burden and Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer. 2020 , 26, 2565-2572	71
310	Differential Depletion of Bone Marrow Resident B-ALL after Systemic Administration of Endosomal TLR Agonists. 2020 , 12,	1
309	TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials. 2020 , 27, 841-853	32
308	Homologous Recombination Repair Truncations Predict Hypermutation in Microsatellite Stable Colorectal and Endometrial Tumors. 2020 , 11, e00149	0

307	Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project. 2020 , 8,	125
306	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. 2020 , 8,	233
305	The Promise of Combining Radiation Therapy With Immunotherapy. 2020 , 108, 6-16	43
304	Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences. 2020 , 44, 649-656	25
303	Mechanisms and therapeutic implications of hypermutation in gliomas. 2020 , 580, 517-523	172
302	pyCancerSig: subclassifying human cancer with comprehensive single nucleotide, structural and microsatellite mutational signature deconstruction from whole genome sequencing. 2020 , 21, 128	1
301	DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor. 2020 , 33, 1910-1921	16
300	PD-1/PD-L1 immune checkpoint inhibitors in glioblastoma: clinical studies, challenges and potential. 2021 , 17, 546-553	10
299	High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient. 2021 , 70, 831-842	8
298	Ultra-mutated colorectal cancer patients with POLE driver mutations exhibit distinct clinical patterns. 2021 , 10, 135-142	7
297	Sarcomas of Bone and Soft Tissues in Children and Adolescents. 2021 ,	0
296	Genome and Transcriptome Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors. 2021 , 27, 202-212	19
295	Mutation-selection balance and compensatory mechanisms in tumour evolution. 2021 , 22, 251-262	16
294	Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis. 2021 , 141, 85-100	14
293	Defining the Comprehensive Genomic Landscapes of Pancreatic Ductal Adenocarcinoma Using Real-World Endoscopic Aspiration Samples. 2021 , 27, 1082-1093	2
292	Role of Tumor Mutation Burden Analysis in Detecting Lynch Syndrome in Precision Medicine: Analysis of 2,501 Japanese Cancer Patients. 2021 , 30, 166-174	1
291	Post-treatment hypermutation in a recurrent diffuse glioma with H3.3 p.G34 Mutation. 2021 , 47, 460-463	1
290	Near Full-Length Genomic Characterization of a Novel HIV-1 Circulating Recombinant Form (CRF107_01B) Identified Among Men Who Have Sex with Men in Heilongjiang Province of China. 2021 , 37, 151-156	1

289	Unraveling the genomic landscape of colorectal cancer through mutational signatures. 2021 , 151, 385-424	2
288	Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT).. 2021 , 5, 215-226	7
287	Use of Antiangiogenic Therapies in Pediatric Solid Tumors. 2021 , 13,	4
286	Distinctive genomic characteristics in -mutant cancers can potentially predict beneficial clinical outcomes in patients who receive immune checkpoint inhibitor. 2021 , 9, 129	9
285	Immunotherapy in colorectal cancer. 2021 , 151, 137-196	6
284	Diagnosis of Lynch Syndrome and Strategies to Distinguish Lynch-Related Tumors from Sporadic MSI/dMMR Tumors. 2021 , 13,	11
283	Clinicopathological and molecular characteristics of patients with hypermutant lung cancer: A retrospective cohort study. 2021 , 21, 329	1
282	Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition. 2021 , 11, 1454-1467	6
281	Mutational concordance analysis provides supportive information for double cancer diagnosis. 2021 , 21, 181	0
280	Molecular Profiling of 22 Primary Atypical Meningiomas Shows the Prognostic Significance of 18q Heterozygous Loss and Homozygous Deletion on Recurrence-Free Survival. 2021 , 13,	4
279	Sequence neighborhoods enable reliable prediction of pathogenic mutations in cancer genomes.	
278	Hypermutated phenotype in gliosarcoma of the spinal cord. 2021 , 5, 8	2
277	Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group. 2021 ,	11
276	Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an -Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report-Usage of Immune Checkpoint Inhibition in CMMRD. 2021 , 28, 757-766	4
275	Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas. 2021 , 34, 1245-1260	2
274	Germline and Tumor Sequencing as a Diagnostic Tool To Resolve Suspected Lynch Syndrome. 2021 , 23, 358-371	1
273	The evolving paradigm of biomarker actionability: Histology-agnosticism as a spectrum, rather than a binary quality. 2021 , 94, 102169	4
272	Mutagenic mechanisms of cancer-associated DNA polymerase ϵ alleles. 2021 , 49, 3919-3931	2

271	The Landscape of Alterations in DNA Damage Response Pathways in Colorectal Cancer. 2021 , 27, 3234-3242	5
270	Identification of a signature of evolutionarily conserved stress-induced mutagenesis in cancer.	
269	Interfaces between cellular responses to DNA damage and cancer immunotherapy. 2021 , 35, 602-618	16
268	Combined vaccine-immune-checkpoint inhibition constitutes a promising strategy for treatment of dMMR tumors. 2021 , 70, 3405-3419	0
267	Life without mismatch repair.	6
266	Examination of gene loss in the DNA mismatch repair pathway and its mutational consequences in a fungal phylum.	1
265	A systematic CRISPR screen defines mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage. 2021 , 2, 643-657	25
264	Personal Neoantigens From Patients With NSCLC Induce Efficient Antitumor Responses. 2021 , 11, 628456	3
263	Temozolomide-induced hypermutation is associated with distant recurrence and reduced survival after high-grade transformation of low-grade IDH-mutant gliomas. 2021 , 23, 1872-1884	9
262	Targeting the CSF1/CSF1R axis is a potential treatment strategy for malignant meningiomas. 2021 , 23, 1922-1935	5
261	Integrated approaches for precision oncology in colorectal cancer: The more you know, the better. 2021 ,	1
260	The Role of Mismatch Repair in Glioblastoma Multiforme Treatment Response and Resistance. 2021 , 32, 171-180	1
259	The Challenge of Diagnosing Constitutional Mismatch Repair Deficiency Syndrome in Brain Malignancies from Young Individuals. 2021 , 22,	1
258	MetaMutationalSigs: Comparison of mutational signature refitting results made easy.	
257	An integrative analysis of the age-associated multi-omic landscape across cancers. 2021 , 12, 2345	9
256	RNA-Seq Reveals Differences in Expressed Tumor Mutation Burden in Colorectal and Endometrial Cancers with and without Defective DNA-Mismatch Repair. 2021 , 23, 555-564	9
255	Toward a Personalized Therapy in Soft-Tissue Sarcomas: State of the Art and Future Directions. 2021 , 13,	1
254	Sequence Neighborhoods Enable Reliable Prediction of Pathogenic Mutations in Cancer Genomes. 2021 , 13,	1

253	Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer. 2021 , 53, 1088-1096	16
252	KIF18B is a Prognostic Biomarker and Correlates with Immune Infiltrates in Pan-Cancer. 2021 , 8, 559800	3
251	Are Molecular Alterations Linked to Genetic Instability Worth to Be Included as Biomarkers for Directing or Excluding Melanoma Patients to Immunotherapy?. 2021 , 11, 666624	1
250	Protein structural consequences of DNA mutational signatures: A meta-analysis of somatic variants and deep mutational scanning data.	
249	SWI/SNF-deficient undifferentiated/rhabdoid carcinoma of the gallbladder carrying a POLE mutation in a 30-year-old woman: a case report. 2021 , 16, 52	1
248	Molecular and Radiological Features of Microsatellite Stable Colorectal Cancer Cases With Dramatic Responses to Immunotherapy. 2021 , 41, 2985-2992	0
247	FDA-Approved and Emerging Next Generation Predictive Biomarkers for Immune Checkpoint Inhibitors in Cancer Patients. 2021 , 11, 683419	17
246	Prädiktive Biomarker in der immunonkologischen Therapie gastrointestinaler Tumoren: derzeitiger Standard und zukünftige Perspektiven. 2021 , 16, 224-240	
245	DNA Damage Repair Gene Set as a Potential Biomarker for Stratifying Patients with High Tumor Mutational Burden. 2021 , 10,	0
244	Framing the potential of public frameshift peptides as immunotherapy targets in colon cancer. 2021 , 16, e0251630	0
243	Biomarkers of therapeutic response with immune checkpoint inhibitors. 2021 , 9, 1040	1
242	Advances in immunotherapeutic targets for childhood cancers: A focus on glypican-2 and B7-H3. 2021 , 223, 107892	4
241	Genomes for Kids: The Scope of Pathogenic Mutations in Pediatric Cancer Revealed by Comprehensive DNA and RNA Sequencing. 2021 ,	21
240	Neurocytological Advances in the Treatment of Glioblastoma Multiforme. 2021 , 13, e16301	0
239	The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma. 2021 , 19, 301	2
238	SUITOR: selecting the number of mutational signatures through cross-validation.	
237	Detection and characterization of replication origins defined by DNA polymerase epsilon.	0
236	Ultra-Deep Sequencing Reveals the Mutational Landscape of Classical Hodgkin Lymphoma.	

235	Somatic Tumor Profile Analysis in a Patient with Germline Mutation and Synchronous Ovarian and Uterine Carcinomas. 2021 , 11,	1
234	[Current landscape of biomarker development for immune checkpoint inhibitors targeting PD-1/PD-L1 pathway in oncology]. 2021 , 76, 597-615	0
233	Pursuing Precision: Receptor Tyrosine Kinase Inhibitors for Treatment of Pediatric Solid Tumors. 2021 , 13,	1
232	Mutational signatures: emerging concepts, caveats and clinical applications. 2021 , 21, 619-637	13
231	Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer. 2021 ,	0
230	Mechanisms of targeted therapy resistance in a pediatric glioma driven by fusion. 2021 , 7,	2
229	Tumor testing can reveal a high tumor mutational burden related to pathogenic variants. 2021 , 37, 100855	
228	Combination strategies of immunotherapy in non-small cell lung cancer: facts and challenges. 2021 , 134, 1908-1919	
227	Rare cases of medulloblastoma with hypermutation. 2021 , e1521	
226	Comprehensive Analysis of Co-Mutations Identifies Cooperating Mechanisms of Tumorigenesis.	
225	The Landscape of Pediatric Precision Oncology: Program Design, Actionable Alterations, and Clinical Trial Development. 2021 , 13,	2
224	Mutational burden and immune recognition of gliomas. 2021 , 33, 626-634	0
223	POLE, POLD1, and NTHL1: the last but not the least hereditary cancer-predisposing genes. 2021 , 40, 5893-5901	8
222	Upfront Adjuvant Immunotherapy of Replication Repair-Deficient Pediatric Glioblastoma With Chemoradiation-Sparing Approach.. 2021 , 5, 1426-1431	0
221	Canine tumor mutational burden is correlated with TP53 mutation across tumor types and breeds. 2021 , 12, 4670	4
220	Linking Immunity with Genomics in Sarcomas: Is Genomic Complexity an Immunogenic Trigger?. 2021 , 9,	0
219	The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer. 1	6
218	Survival Benefit for Individuals With Constitutional Mismatch Repair Deficiency Undergoing Surveillance. 2021 , 39, 2779-2790	10

217	Updates in the molecular pathology of non-small cell lung cancer. 2021 , 38, 54-61	3
216	Hypermutation, Mismatch Repair Deficiency, and Defining Predictors of Response to Checkpoint Blockade. 2021 ,	2
215	Clinical Efficacy and Future Prospects of Immunotherapy in Lung Cancer. 2021 , 11,	2
214	The Evolving Role of Radiotherapy for Pediatric Cancers With Advancements in Molecular Tumor Characterization and Targeted Therapies. 2021 , 11, 679701	1
213	POLE/POLD1 mutation in non-exonuclease domain matters for predicting efficacy of immune-checkpoint-inhibitor therapy. 2021 , 11, e524	1
212	TP53 variant allele frequency correlates with the chemotherapy response score in ovarian/fallopian tube/peritoneal high-grade serous carcinoma. 2021 , 115, 76-83	
211	Transcriptome sequencing reveals <i>Gastrodia elata</i> Blume could increase the cell viability of eNPCs under hypoxic condition by improving DNA damage repair ability. 2022 , 282, 114646	0
210	Systematic review of the immunological landscape of Wilms tumors. 2021 , 22, 454-467	5
209	Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers. 2021 , 9,	5
208	Bromodomain proteins: protectors against endogenous DNA damage and facilitators of genome integrity. 2021 , 53, 1268-1277	4
207	Examination of Gene Loss in the DNA Mismatch Repair Pathway and Its Mutational Consequences in a Fungal Phylum. 2021 , 13,	4
206	Eliciting an immune-mediated antitumor response through oncolytic herpes simplex virus-based shared antigen expression in tumors resistant to viroimmunotherapy. 2021 , 9,	
205	Targeted and immuno-based therapies in sarcoma: mechanisms and advances in clinical trials. 2021 , 1876, 188606	2
204	Clinical utility of comprehensive genomic profiling in central nervous system tumors of children and young adults. 2021 , 3, vdab037	0
203	Identification of New Genes Involved in Germline Predisposition to Early-Onset Gastric Cancer. 2021 , 22,	3
202	Priming and Propagating Anti-tumor Immunity: Focal Hypofractionated Radiation for in Situ Vaccination and Systemic Targeted Radionuclide Theranostics for Immunomodulation of Tumor Microenvironments. 2020 , 30, 181-186	11
201	Canine tumor mutation rate is positively correlated with TP53 mutation across cancer types and breeds.	3
200	Dissecting mutational mechanisms underpinning signatures caused by replication errors and endogenous DNA damage.	10

199	Mutagenic mechanisms of cancer-associated DNA polymerase β alleles.	1
198	Prioritisation of oncology therapeutic targets using CRISPR-Cas9 screening.	2
197	A stress response that allows highly mutated eukaryotic cells to survive and proliferate.	0
196	Pediatric High Grade Glioma Resources From the Children’s Brain Tumor Tissue Consortium (CBTTC) and Pediatric Brain Tumor Atlas (PBTA).	2
195	5-Fluorouracil treatment induces characteristic T>G mutations in human cancer.	1
194	The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research.	3
193	Prevalence and mutational determinants of high tumor mutation burden in breast cancer.	0
192	Efficacy of pembrolizumab in patients with pituitary carcinoma: report of four cases from a phase II study. 2020 , 8,	12
191	DNA Polymerase and Mismatch Repair Exert Distinct Microsatellite Instability Signatures in Normal and Malignant Human Cells. 2021 , 11, 1176-1191	19
190	Mutational landscape in genetically engineered, carcinogen-induced, and radiation-induced mouse sarcoma. 2019 , 4,	26
189	A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response. 2020 , 5,	10
188	Polymerase-mediated ultramutagenesis in mice produces diverse cancers with high mutational load. 2018 , 128, 4179-4191	36
187	Polymerase β deficiency causes syndromic immunodeficiency with replicative stress. 2019 , 129, 4194-4206	20
186	Immune profiling of pediatric solid tumors. 2020 , 130, 3391-3402	12
185	Case report: recurrent pituitary adenoma has increased load of somatic variants. 2020 , 20, 17	2
184	POLE and POLD1 pathogenic variants in the proofreading domain in papillary thyroid cancer. 2020 , 9, 923-932	2
183	Genomic characterization of metastatic ultra-hypermutated interdigitating dendritic cell sarcoma through rapid research autopsy. 2019 , 10, 277-288	5
182	Heterogeneity in the lymphocytic infiltration of deficient DNA mismatch repair colon cancers. 2018 , 9, 36722-36723	1

181	Pediatric High Grade Gliomas in the Context of Cancer Predisposition Syndromes. 2018 , 61, 319-332	16
180	Implications of driver genes associated with a high tumor mutation burden identified using next-generation sequencing on immunotherapy in hepatocellular carcinoma. 2020 , 19, 2739-2748	10
179	Recent advances of single-cell RNA sequencing technology in mesenchymal stem cell research. 2020 , 12, 438-447	4
178	Explosive mutation accumulation triggered by heterozygous human Pol δ proofreading-deficiency is driven by suppression of mismatch repair. 2018 , 7,	19
177	Distinct mutational profile and immune microenvironment in microsatellite-unstable and -mutated tumors. 2021 , 9,	4
176	Lineage Recording Reveals the Phylodynamics, Plasticity and Paths of Tumor Evolution.	0
175	Mouse model and human patient data suggest critical roles for Pten and p53 in suppressing POLE mutant tumor development.	
174	Genomic and Transcriptomic Analysis of Relapsed and Refractory Childhood Solid Tumors Reveals a Diverse Molecular Landscape and Mechanisms of Immune Evasion. 2021 , 81, 5818-5832	1
173	A systematic analysis of genetic interactions and their underlying biology in childhood cancer. 2021 , 4, 1139	0
172	Modeling Functional Genetic Alteration in Cancer Reveals New Candidate Driver Genes.	
171	Recapitulation of human germline coding variation in an ultra-mutated infant leukemia.	
170	Criticality in Tumor Evolution and Clinical Outcome.	
169	Comprehensive analysis of potential immunotherapy genomic biomarkers in 1,000 Chinese patients with cancer.	
168	A simple but profound mutation in mouse DNA polymerase δ drives tumorigenesis. 2018 , 128, 3754-3756	0
167	Clinical sequencing of pancreatic cancer in clinical practice. 2018 , 33, 915-922	
166	Proteomic and Genomic Signatures of Repeat-instability in Cancer and Adjacent Normal Tissues.	1
165	Extensive loss of cell cycle and DNA repair genes in an ancient lineage of bipolar budding yeasts.	1
164	ecTMB: a robust method to estimate and classify tumor mutational burden.	

- 163 Bioinformatic Methods and Bridging of Assay Results for Reliable Tumor Mutational Burden Assessment in Non-Small Cell Lung Cancer.
- 162 Mutational processes of distinct POLE exonuclease domain mutants drive an enrichment of a specific TP53 mutation in colorectal cancer.
- 161 Spontaneous polyploids and antimutators compete during the evolution of mutator cells.
- 160 Personalizing Precision Oncology: From Light Microscope to Molecular Microscope. **2019**, 17, 886-888
- 159 Prognostic Factors and Risk Stratification. **2020**, 271-292
- 158 Unraveling the heterogeneous mutational signature of spontaneously developing tumors in MLH1-/-mice.
- 157 pyCancerSig: subclassifying human cancer with comprehensive single nucleotide, structural and microsatellite mutational signature deconstruction from whole genome sequencing.
- 156 Matching cell lines with cancer type and subtype of origin via mutational, epigenomic and transcriptomic patterns. 0
- 155 Immunotherapy in Pediatric Solid Tumors. **2020**, 27, 22-31
- 154 An Integrative Analysis of the Age-Associated Genomic, Transcriptomic and Epigenetic Landscape across Cancers. 1
- 153 Optimizing the evaluation of gene-targeted panels for tumor mutational burden estimation. **2021**, 11, 21072 0
- 152 Commercial ctDNA Assays for Minimal Residual Disease Detection of Solid Tumors. **2021**, 25, 757-774 2
- 151 The contribution of evolutionary game theory to understanding and treating cancer. 4
- 150 Dissecting the Functional Significance of DNA Polymerase Mutations in Cancer. **2020**, 80, 5459-5461
- 149 Prolonged benefit to pembrolizumab in anaplastic oligodendroglioma patient with mismatch repair deficiency: a case report. **2021**, 32, 218-221 0
- 148 Adaptive Immunity and the Tumor Microenvironment. **2020**, 180, 111-147 1
- 147 Targeting the Immune System in Pancreatic Cancer. **2020**, 203-218
- 146 Germline and Tumor Whole Genome Sequencing as a Diagnostic Tool to Resolve Suspected Lynch Syndrome. 0

- 145 Molecular characteristics and clinical outcomes of patients with Neurofibromin 1-altered metastatic colorectal cancer. **2021**, 2
- 144 Functional pre-therapeutic evaluation by genome editing of variants of uncertain significance of essential tumor suppressor genes. **2021**, 13, 174 1
- 143 Immunotherapy for Pediatric Sarcomas. **2021**, 165-180
- 142 Mechanisms Underlying Mutational Signatures in Human Cancer. 526-540
- 141 The conversion of RAS status in metastatic colorectal cancer patients after first-line biological agent treatment. **2021**, 23, 206-212
- 140 Pediatric Surgical Perspective to Colon Polyps and Colorectal Carcinomas. **2021**, 515-527
- 139 RRM2B is frequently amplified across multiple tumor types: non-oncogenic addiction and therapeutic opportunities.
- 138 A comprehensive map of genetic interactions in childhood cancer reveals multiple underlying biological mechanisms.
- 137 Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own?. **2020**, 8, 1112
- 136 Evaluation of Classic, Attenuated, and Oligopolyposis of the Colon. **2022**, 32, 95-112
- 135 Identification and validation of neoantigens for immune activation against high-risk pediatric leukemia cells. **2021**, 1-5
- 134 Genetic Cancer Susceptibility in Adolescents and Adults 25 Years or Younger with Colorectal Cancer. **2021**, 0
- 133 Liquid biopsies in pediatric oncology: opportunities and obstacles. **2021**, 34, 0
- 132 Constitutional POLE variants causing a phenotype reminiscent of constitutional mismatch repair deficiency. **2021**, 43, 85 1
- 131 Genomic landscape and clinical utility of Korean advanced pan-cancer patients from prospective clinical sequencing: K-MASTER program. **2021**, 4
- 130 Genomic predictors of response to PD-1 inhibition in children with germline DNA replication repair deficiency.. **2022**, 2
- 129 ScalpelSig Designs Targeted Genomic Panels from Data to Detect Activity of Mutational Signatures.. **2022**,
- 128 A novel POLD1 pathogenic variant identified in two families with a cancer spectrum mimicking lynch syndrome.. **2021**, 65, 104409

127	Pembrolizumab (and friends) in pediatric malignancies: should we consider Hodgkin lymphoma a world of its own?. 2020 , 8, 1112-1112	
126	Biomarkers for Immunotherapy in Gastrointestinal Cancers. 2021 ,	
125	Germline predisposition to glial neoplasms in children and young adults: A narrative review. 2021 , 4, 68	
124	Immunotherapy for Neuro-oncology.. 2021 , 1342, 233-258	1
123	Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better.. 2022 , 10,	5
122	Di-genic inheritance of germline POLE and PMS2 pathogenic variants causes a unique condition associated with pediatric cancer predisposition.. 2021 ,	1
121	Secreted phosphoprotein 1 as a potential prognostic and immunotherapy biomarker in multiple human cancers.. 2022 , 13, 3221-3239	0
120	Childhood Medulloblastoma: An Overview.. 2022 , 2423, 1-12	
119	Comprehensive Analysis of Co-Mutations Identifies Cooperating Mechanisms of Tumorigenesis.. 2022 , 14,	0
118	Probing the mechanisms of two exonuclease domain mutators of DNA polymerase ?.. 2022 ,	1
117	PrimPol: A Breakthrough among DNA Replication Enzymes and a Potential New Target for Cancer Therapy.. 2022 , 12,	0
116	Clinical and Molecular Characterization of Mutations as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors in Advanced Cancers.. 2022 , 6, e2100267	2
115	Therapeutic implications of germline vulnerabilities in DNA repair for precision oncology.. 2022 , 104, 102337	0
114	Neurotrophic tyrosine receptor kinase fusion in pediatric central nervous system tumors.. 2022 , 262-263, 64-70	0
113	MetaMutationalSigs: Comparison of mutational signature refitting results made easy.. 2022 ,	
112	FOXM1/lncRNA TYMSOS/miR-214-3p-Mediated High Expression of NCAPG Correlates With Poor Prognosis and Cell Proliferation in Non-Small Cell Lung Carcinoma.. 2021 , 8, 785767	0
111	Somatic mutational profiles and germline polygenic risk scores in human cancer.. 2022 , 14, 14	0
110	A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability. 2021 ,	6

109	Mouse model and human patient data reveal critical roles for Pten and p53 in suppressing POLE mutant tumor development.. 2022 , 4, zcac004	0
108	Immune Checkpoint Inhibitors in Triple Negative Breast Cancer: The Search for the Optimal Biomarker.. 2022 , 17, 11772719221078774	0
107	Pan-Cancer Analysis and Validation Reveals that D-Dimer-Related Genes are Prognostic and Downregulate CD8 T Cells TGF-Beta Signaling in Gastric Cancer.. 2022 , 9, 790706	1
106	Genetic immune escape landscape in primary and metastatic cancer.	0
105	Genetic Characteristics Associated With Drug Resistance in Lung Cancer and Colorectal Cancer Using Whole Exome Sequencing of Cell-Free DNA.. 2022 , 12, 843561	0
104	Identification of Ferroptosis-Related Genes as Biomarkers for Sarcoma.. 2022 , 10, 847513	0
103	APOBEC Mutational Signature and Tumor Mutational Burden as Predictors of Clinical Outcomes and Treatment Response in Patients With Advanced Urothelial Cancer.. 2022 , 12, 816706	0
102	Temozolomide Followed by Combination With Low-Dose Ipilimumab and Nivolumab in Patients With Microsatellite-Stable, O-Methylguanine-DNA Methyltransferase-Silenced Metastatic Colorectal Cancer: The MAYA Trial.. 2022 , JCO2102583	4
101	Four-Year Disease-Free Remission in a Patient With POLE Mutation-Associated Colorectal Cancer Treated Using Anti-PD-1 Therapy.. 2022 , 20, 218-223	0
100	Molecular Characterization Clinical and Immunotherapeutic Characteristics of m5C Regulator NOP2 Across 33 Cancer Types.. 2022 , 10, 839136	0
99	DNA repair defects in cancer and therapeutic opportunities.. 2022 , 36, 278-293	2
98	Immune Checkpoint Inhibition as Single Therapy for Synchronous Cancers Exhibiting Hypermutation: An IRRDC Study.. 2022 , 6, e2100286	1
97	HSP90 inhibition overcomes resistance to molecular targeted therapy in BRAFV600E mutant high-grade glioma.. 2022 ,	1
96	SUITOR: Selecting the number of mutational signatures through cross-validation.. 2022 , 18, e1009309	0
95	Current Prognostic and Predictive Biomarkers for Endometrial Cancer in Clinical Practice: Recommendations/Proposal from the Italian Study Group.. 2022 , 12, 805613	2
94	Homologous recombination deficiency is inversely correlated with microsatellite instability and identifies immunologically cold tumors in most cancer types.. 2022 ,	1
93	Genomic and single-cell landscape reveals novel drivers and therapeutic vulnerabilities of transformed cutaneous T-cell lymphoma.. 2022 ,	3
92	A Multiplex SNaPshot Assay is a Rapid and Cost-Effective Method for Detecting POLE Exonuclease Domain Mutations in Endometrial Carcinoma.. 2021 ,	1

91	IDH-wild type glioblastomas featuring at least 30% giant cells are characterized by frequent RB1 and NF1 alterations and hypermutation.. 2021 , 9, 200	0
90	A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era.. 2021 ,	5
89	Molecular characterization of extrahepatic cholangiocarcinoma: perihilar and distal tumours display divergent genomic and transcriptomic profiles. 2021 ,	2
88	Evaluation of IL-2 and Dexamethasone intracavitary injection on the management of malignant effusion in children with solid tumors or lymphoma. 2021 , 21, 1302	1
87	PD-1 blockade in solid tumors with defects in polymerase epsilon.. 2022 ,	1
86	Assessing the importance of resistance, persistence and hyper-mutation for antibiotic treatment success with stochastic modelling.	1
85	DNA damage response and repair in the development and treatment of brain tumors.. 2022 , 924, 174957	
84	Data_Sheet_1.DOCX. 2020 ,	
83	Table_1.xls. 2020 ,	
82	Data_Sheet_1.docx. 2019 ,	
81	Data_Sheet_2.xlsx. 2019 ,	
80	Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy.. 2022 ,	1
79	Pan-Cancer Analysis of Microfibrillar-Associated Protein 2 (MFAP2) Based on Bioinformatics and qPCR Verification.. 2022 , 2022, 8423173	0
78	Development of a Novel Reference Material for Tumor Mutational Burden Measurement Based on CRISPR/Cas9 Technology.. 2022 , 12, 845636	
77	Substitution mutational signatures in whole-genome sequenced cancers in the UK population. 2022 , 376,	7
76	Comprehensive profiling of 1015 patients' exomes reveals genomic-clinical associations in colorectal cancer.. 2022 , 13, 2342	0
75	Biomarkers of Response and Resistance to Immunotherapy in Microsatellite Stable Colorectal Cancer: Toward a New Personalized Medicine.. 2022 , 14,	1
74	The Cellular Tumor Immune Microenvironment of Childhood Solid Cancers: Informing More Effective Immunotherapies.. 2022 , 14,	

73	Hereditary Colorectal Cancer.. 2022 ,		2
72	Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB.. 2022 , 23,		
71	Lineage tracing reveals the phylodynamics, plasticity, and paths of tumor evolution.. <i>Cell</i> , 2022 ,	56.2	4
70	High tumor mutational burden (TMB) identifies a microsatellite stable pancreatic cancer subset with prolonged survival and strong anti-tumor immunity.. 2022 , 169, 64-73		2
69	Paired Tumor-Germline Testing as a Driver in Better Cancer Care.. 2022 , 5, e2213077		0
68	Feasibility of whole genome and transcriptome profiling in pediatric and young adult cancers.. 2022 , 13, 2485		4
67	Checkpoint Immunotherapy in Pediatrics: Here, Gone, and Back Again.. 2022 , 42, 1-14		1
66	Signatures of defective DNA repair and replication in early-onset renal cancer patients referred for germline genetic testing.		
65	High prevalence of unusual KRAS , NRAS and BRAF mutations in POLE hypermutated colorectal cancers.		
64	Identifying colorectal cancer caused by biallelic MUTYH pathogenic variants using tumor mutational signatures. 2022 , 13,		0
63	Deep Sequencing of Early T Stage Colorectal Cancers Reveals Disruption of Homologous Recombination Repair in Microsatellite Stable Tumours with High Mutational Burdens. 2022 , 14, 2933		
62	Hypermutation as a potential predictive biomarker of immunotherapy efficacy in high-grade gliomas: a broken dream?.		1
61	Immunotherapy in Sarcoma. 2022 , 31, 381-397		0
60	Tumor Infiltrating Lymphocytes in Breast Cancer: Implementation of a New Histopathological Biomarker. 2022 , 207-243		1
59	Age-associated differences in the cancer molecular landscape. 2022 ,		0
58	A comprehensive prognostic and immune analysis of enhancer RNA identifies IGFBP7-AS1 as a novel prognostic biomarker in Uterine Corpus Endometrial Carcinoma. 2022 , 24,		0
57	Immune checkpoint blockade in hormone receptor-positive breast cancer: Resistance mechanisms and future perspectives. 2022 ,		
56	Functional landscapes of POLE and POLD1 mutations in checkpoint blockade-dependent antitumor immunity. 2022 , 54, 996-1012		4

55	Enhanced polymerase activity permits efficient synthesis by cancer-associated DNA polymerase ? variants at low dNTP levels.	
54	Colorectal cancer immunotherapy-Recent progress and future directions. 2022 , 545, 215816	1
53	ALT in Pediatric Brain Tumors Can Occur without ATRX Mutation and is Enriched in Patients with Pathogenic Germline MMR Variants.	
52	A Selective Reduction of Osteosarcoma by Mitochondrial Apoptosis Using Hydroxyapatite Nanoparticles. Volume 17, 3691-3710	0
51	Special Considerations in the Molecular Diagnostics of Pediatric Neoplasms. 2022 ,	
50	Comprehensive Analysis of Gene Signatures of m6ARNA Methylation Regulators in Lung Adenocarcinoma and Development of a Risk Scoring System. 2022 , 2022, 1-16	
49	Tumor mutation burden-assisted risk stratification for papillary thyroid cancer.	0
48	Enhanced immune response outperform aggressive cancer biology and is associated with better survival in triple-negative breast cancer. 2022 , 8,	
47	Clinical implementation of plasma cell-free circulating tumor DNA quantification by digital droplet PCR for the monitoring of Ewing sarcoma in children and adolescents. 10,	0
46	Immune checkpoint blockade in pancreatic cancer: Trudging through the immune desert. 2022 , 86, 14-27	2
45	High Tumor Mutation Burden Is Associated with Poor Clinical Outcome in EGFR-Mutated Lung Adenocarcinomas Treated with Targeted Therapy. 2022 , 10, 2109	0
44	TMBur: a distributable tumor mutation burden approach for whole genome sequencing. 2022 , 15,	1
43	OpenPBTA: An Open Pediatric Brain Tumor Atlas.	0
42	Identification of a signature of evolutionarily conserved stress-induced mutagenesis in cancer. 13,	0
41	Teenage-Onset Colorectal Cancers in a Digenic Cancer Predisposition Syndrome Provide Clues for the Interaction between Mismatch Repair and Polymerase I Proofreading Deficiency in Tumorigenesis. 2022 , 12, 1350	1
40	An international working group consensus report for the prioritization of molecular biomarkers for Ewing sarcoma. 2022 , 6,	1
39	Evolution of precision oncology-guided treatment paradigms.	0
38	Local TLR4 stimulation augments in situ vaccination induced via local radiation and anti-CTLA-4 checkpoint blockade through induction of CD8 T-cell independent Th1 polarization. 2022 , 10, e005103	1

- 37 Genomic Microsatellite Signatures Identify Germline Mismatch Repair Deficiency and Risk of Cancer Onset. ○
- 36 Noncoding RNAs-mediated overexpression of KIF14 is associated with tumor immune infiltration and unfavorable prognosis in lung adenocarcinoma. **2022**, 14, 8013-8031 ○
- 35 Chemopreventive role of probiotics against cancer: a comprehensive mechanistic review. ○
- 34 Somatic mutation distribution across tumour cohorts provides a signal for positive selection in cancer. **2022**, 13, 1 ○
- 33 Radiosensitization-Related Cuproptosis LncRNA Signature in Non-Small Cell Lung Cancer. **2022**, 13, 2080 ○
- 32 Assessing the relative importance of bacterial resistance, persistence and hyper-mutation for antibiotic treatment failure. **2022**, 289, ○
- 31 Stellenwert der genetischen Testung beim Prostatakarzinom. ○
- 30 Genomic and Transcriptomic Predictors of Response to Immune Checkpoint Inhibitors in Melanoma Patients: A Machine Learning Approach. **2022**, 14, 5605 ○
- 29 The Somatic Mutation Landscape of UDP-Glycosyltransferase (UGT) Genes in Human Cancers. **2022**, 14, 5708 ○
- 28 Widespread hypertranscription in aggressive human cancers. **2022**, 8, 1
- 27 Therapie des Rektumkarzinoms und DNA-Mismatch-Reparatur-Defizienz mittels Immuncheckpoint-Inhibitoren. **2022**, 44, 423-424 ○
- 26 Distinct clinical pattern of colorectal cancer patients with POLE mutations: A retrospective study on real-world data. 13, ○
- 25 Genomic disparities between cancers in adolescent and young adults and in older adults. **2022**, 13, ○
- 24 Co-occurring mutations in the POLE exonuclease and non-exonuclease domains define a unique subset of highly mutagenic tumors. ○
- 23 ALT in Pediatric High-Grade Gliomas Can Occur without ATRX Mutation and is Enriched in Patients with Pathogenic Germline MMR Variants. ○
- 22 Racial/ethnic and sex differences in somatic cancer gene mutations among patients with early-onset colorectal cancer. 1
- 21 Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker. 13, ○
- 20 Unique Patterns of Heterogeneous Mismatch Repair Protein Expression in Colorectal Cancer Unveil Different Degrees of Tumor Mutational Burden and Distinct Tumor Microenvironment Features. **2023**, 100012 1

- 19 The clinical utility of integrative genomics in childhood cancer extends beyond targetable mutations. ○
- 18 Constitutional microsatellite instability, genotype, and phenotype correlations in Constitutional Mismatch Repair Deficiency. **2022**, ○
- 17 Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab. ○
- 16 Mutated axon guidance gene PLXNB2 sustains growth and invasiveness of stem cells isolated from cancers of unknown primary. **2023**, 15, 1 ○
- 15 Challenges and Therapeutic Opportunities in the dMMR/MSI-H Colorectal Cancer Landscape. **2023**, 15, 1022 ○
- 14 Using comprehensive genomic and functional analyses for resolving genotype-phenotype mismatches in children with suspected CMMRD in Lebanon: an IRRDC study. **2023**, 142, 563-576 ○
- 13 Detection and characterization of constitutive replication origins defined by DNA polymerase epsilon. **2023**, 21, ○
- 12 Development of Prognostic Biomarkers by TMB-Guided WSI Analysis: A Two-Step Approach. **2023**, 1-9 ○
- 11 Characterization of POLE c.1373A > T p.(Tyr458Phe), causing high cancer risk. ○
- 10 GASTROINTESTINAL CANCER SYNDROMES. **2023**, 35-128 ○
- 9 A Biterm Topic Model for Sparse Mutation Data. **2023**, 15, 1601 ○
- 8 Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond. **2023**, 15, 1643 ○
- 7 The hereditary N363K POLE exonuclease mutant extends PPAP tumor spectrum to glioblastomas by causing DNA damage and aneuploidy in addition to increased mismatch mutagenicity. **2023**, 5, ○
- 6 Case report: a glioma patient diagnosed as constitutional mismatch repair deficiency syndrome (CMMRD) with a de novo germline variant in PMS2. ○
- 5 New therapeutics for soft tissue sarcomas: Overview of current immunotherapy and future directions of soft tissue sarcomas. 13, ○
- 4 Integrative multi-omic sequencing reveals the MMTV-Myc mouse model mimics human breast cancer heterogeneity. ○
- 3 Comprehensive characterization of FBXW7 mutational and clinicopathological profiles in human colorectal cancers. 13, ○
- 2 Discovery of broadly-neutralizing antibodies against brown recluse spider and Gadim scorpion sphingomyelinases using consensus toxins as antigens. ○

1 DNA polymerase POLD1 promotes proliferation and metastasis of bladder cancer by stabilizing MYC. **2023**, 14,

o